268: Biogen's sticky situation, Wegovy's risks, & biotech insider trading
The Readout Loud
00:00
Biogen's CEO Don't Talk About Zeranalone
A drug called zeranalone is being developed to treat two forms of depression, major depressive disorder, and postpartum depression. A decision on that drug is expected on August 5th. The fact that Chris V. Bakker and the rest of the biogen team didn't talk about it hit Sage's stock. People are going to be a little bit nervous now heading into the Paduvidae.
Transcript
Play full episode
